相关实验视频
Updated: Jul 16, 2025
08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
21.1K
免疫检查点分子DNAM-1/CD112轴是急性髓性白血病自然杀手细胞治疗的新目标
Yuta Kaito1, Emi Sugimoto2, Fumi Nakamura3
1Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Tokyo.
Haematologica
|September 21, 2023
概括
将CD112分子准急性髓性白血病 (AML) 细胞,用修饰的自然杀手 (NK) 细胞进行向,显示出免疫治疗的前景. 这种方法增强了NK细胞的活性,并可作为AML患者的预后标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 由于免疫逃避,急性髓性白血病 (AML) 经常复发.
- 目前针对AML的免疫疗法因缺乏特定抗原而受到限制.
- CD155和CD112是细胞表面分子,涉及免疫相互作用.
研究的目的:
- 调查CD155,CD112和AML治疗反应之间的关联.
- 评估针对DNAM-1/CD112轴用于AML免疫疗法的潜力.
- 为了确定在AML患者中CD112表达的预后值.
主要方法:
- 产生的修饰NK-92细胞系表达DNAX相关分子1 (DNAM-1) 和T细胞免疫球蛋白和ITIM域 (TIGIT).
- 在200个AML初级样本中分析了CD112表达.
- 评估修饰NK-92细胞对AML细胞系和原始细胞的细胞毒性活性.
- 使用异种移植模型来确认体内治疗效果.
主要成果:
- 在AML患者中,高CD112表达与较短的存活时间相关.
- NK-92 DNAM-1 细胞对AML细胞表现出增强的细胞毒性活性.
- 在NK-92细胞中DNAM-1诱导促进了细胞毒性相关的基因表达,克服了TIGIT抑制.
- CD112被确定为NK细胞基AML治疗的关键标.
- 一个异种移植模型证实NK-92 DNAM-1的抗瘤效果优于未经修改的NK-92细胞.
结论:
- 修改NK细胞中的DNAM-1/CD112轴代表了针对AML的新且潜在有效的免疫疗法.
- 在AML中,CD112作为自然杀手 (NK) 细胞治疗的可行标.
- CD112表达水平可以作为AML患者的预后标志物.
相关概念视频
01:27Cytotoxic T Cells-mediated Immune Response
956
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
956
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K